Randomized Controlled Trial
Copyright ©The Author(s) 2018.
World J Gastroenterol. Apr 14, 2018; 24(14): 1550-1561
Published online Apr 14, 2018. doi: 10.3748/wjg.v24.i14.1550
Table 2 Recurrence rate of erosive esophagitis: Intergroup differences and non-inferiority test
EndpointLPZ 15 mgVPZ 10 mgVPZ 20 mg
Week 24 (primary endpoint)116.8% (33/196)5.1% (10/197)2.0% (4/201)
Week 12 (secondary endpoint)112.2% (24/196)2.5% (5/197)1.0% (2/201)
ComparisonDifference and 95%CI (%)Non-inferiority, P valueFisher exact test, P value2
Week 24 (primary endpoint)
VPZ 10 mg vs LPZ 15 mg-11.8 [-17.83, -5.69]< 0.00010.0002
VPZ 20 mg vs LPZ 15 mg-14.8 [-20.43, -9.26]< 0.0001< 0.0001
VPZ 10 mg vs VPZ 20 mg-3.1 [-6.71, 0.54]N/A0.1090
Week 12 (secondary endpoint)
VPZ 10 mg vs LPZ 15 mg-9.7 [-14.80, -4.62]< 0.0001N/A
VPZ 20 mg vs LPZ 15 mg-11.2 [-16.04, -6.46]< 0.0001N/A
VPZ 10 mg vs VPZ 20 mg-1.5 [-4.13, 1.05]N/AN/A